资讯

CURE12 分钟
Imdelltra Shows Survival Benefit in Small Cell Lung Cancer
Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...
Le Lézard6 分钟
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress
Travere Therapeutics, Inc., today announced that the Company will present seven abstracts at the upcoming European Renal Association (ERA) Congress in Vienna, Austria, June 4-7. Presentations will ...
finanzen.at42 分钟
U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer
ORION CORPORATION PRESS RELEASE 3 JUNE 2025 at 23.30 EEST           U.S. FDA approves third indication of darolutamide for patients with ...
The American Journal of Managed Care59 分钟
Darolutamide Gains FDA Approval for Metastatic Castration-Sensitive Prostate Cancer
Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and ...